Related Experiment Video

Updated: Nov 18, 2025

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

196

Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis

Rimesh Pal1, Mainak Banerjee2, Urmila Yadav3

  • 1Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India rimesh.ben@gmail.com.

Postgraduate Medical Journal
|February 5, 2021
PubMed

Insights

Statin use in COVID-19 patients was linked to better outcomes in adjusted analyses, despite initial unadjusted data showing no effect. Continue statin therapy, especially for those with comorbidities, during the pandemic.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Observational studies suggest statins may reduce adverse outcomes in COVID-19 patients.
  • Existing data are limited, inconsistent, and lack randomized controlled trials.
  • A comprehensive meta-analysis is needed to clarify the effect of statins on COVID-19 outcomes.

Purpose of the Study:

  • To conduct a meta-analysis of observational studies to summarize the effect of statin use on clinical outcomes in COVID-19 patients.
  • To evaluate both unadjusted and adjusted risk estimates for statin use in COVID-19.
  • To provide an updated summary of evidence regarding statins and COVID-19 outcomes.

Main Methods:

  • Systematic search of PubMed, Scopus, and Web of Science databases up to December 18, 2020.
  • Inclusion of observational studies comparing COVID-19 patients with and without statin use (prior and in-hospital).
  • Quality assessment using the Newcastle-Ottawa Scale and calculation of pooled odds ratios (OR) with 95% confidence intervals (CIs).

Main Results:

  • 14 observational studies with 19,988 COVID-19 patients were included; all were of high/moderate quality.
  • Unadjusted analysis showed no significant association between statin use and improved outcomes (OR 1.02, p=0.94).
  • Adjusted analysis revealed a significant reduction in adverse outcomes with statin use (OR 0.51, p<0.0005).

Conclusions:

  • Statin use is associated with improved clinical outcomes in patients with COVID-19.
  • The findings support the continuation of statin therapy for individuals with comorbidities during the pandemic.
  • Further research, including randomized controlled trials, may be warranted to confirm these findings.
Abstract

Keywords:
infectious diseaseslipid disorders

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

889

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
95
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
91
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
113
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
105
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
70